Related Experiment Video
Updated: May 8, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
Capsid-binding retrovirus restriction factors: discovery, restriction specificity and implications for the
Marta Sanz-Ramos1, Jonathan P Stoye2,1
1Division of Virology, MRC National Institute for Medical Research, The Ridgeway, London NW7 1AA, UK.
Abstract:
The development of drugs against human immunodeficiency virus type 1 infection has been highly successful, and numerous combinational treatments are currently available. However, the risk of the emergence of resistance and the toxic effects associated with prolonged use of antiretroviral therapies have emphasized the need to consider alternative approaches. One possible area of investigation is provided by the properties of restriction factors, cellular proteins that protect organisms against retroviral infection. Many show potent viral inhibition. Here, we describe the discovery, properties and possible therapeutic uses of the group of restriction factors known to interact with the capsid core of incoming retroviruses. This group comprises Fv1, TRIM5α and TRIMCypA: proteins that all act shortly after virus entry into the target cell and block virus replication at different stages prior to integration of viral DNA into the host chromosome. They have different origins and specificities, but share general structural features required for restriction, with an N-terminal multimerization domain and a C-terminal capsid-binding domain. Their overall efficacy makes it reasonable to ask whether they might provide a framework for developing novel antiretroviral strategies.
Insights
Cellular restriction factors like Fv1, TRIM5α, and TRIMCypA inhibit human immunodeficiency virus type 1 replication. These proteins offer a potential framework for developing novel antiretroviral therapies.
Area of Science:
- Virology
- Cellular Biology
- Immunology
Background:
- Current antiretroviral therapies for HIV-1 are effective but face challenges like drug resistance and toxicity.
- Alternative strategies are needed to combat HIV-1 infection.
- Cellular restriction factors are endogenous proteins that inhibit retroviral replication.
Purpose of the Study:
- To explore the potential of restriction factors that target the retroviral capsid core as a novel therapeutic strategy against HIV-1.
- To describe the discovery, properties, and therapeutic applications of Fv1, TRIM5α, and TRIMCypA.
Main Methods:
- Review of existing literature on restriction factors and their mechanisms of action.
- Analysis of the structural features and specificities of Fv1, TRIM5α, and TRIMCypA.
- Evaluation of the therapeutic potential of these factors in blocking HIV-1 replication.
Main Results:
- Fv1, TRIM5α, and TRIMCypA are cellular proteins that restrict retroviral infection by interacting with the capsid core.
- These factors act early in the viral life cycle, inhibiting replication before DNA integration.
- Despite different origins and specificities, they share common structural domains for restriction.
Conclusions:
- Restriction factors targeting the retroviral capsid represent a promising avenue for novel antiretroviral drug development.
- The conserved structural features of these factors provide a basis for designing new therapeutic interventions.
- Further research into Fv1, TRIM5α, and TRIMCypA could lead to innovative strategies against HIV-1.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Retroviruses
Viruses with RNA Genomes
Leaky Scanning
Mechanisms of Retrovirus-induced Cancers

